Vimala Venkatesh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Vimala Venkatesh has a total of 140 co-authors. Here are the top co-authors by number of shared publications:
- Amita Jain
All India Institute of Medical Sciences, Rae Bareli, Uttar Pradesh, India
6 shared publications - Sheetal Verma
Department of Microbiology, King George’s Medical University, Lucknow, Uttar Pradesh, India
6 shared publications - Himanshu Dandu
Department of Medicine, King George's Medical University, Lucknow, IND
3 shared publications - Rashmi
Department of Microbiology, King George’s Medical University, Lucknow, India
3 shared publications - Anjoo Agarwal
Department of Obstetrics & Gynaecology, King George's Medical University, Chowk, Lucknow, U.P., INDIA- 226003
2 shared publications Anuragani Verma
Department of Microbiology, King George’s Medical University, Lucknow, India
2 shared publications
Latest Publications
- 10 June 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1)
Multi-omics insights into immunometabolic dysregulation in neonatal sepsis for precision medicine
Neonatal sepsis remains a major global health challenge, contributing substantially to morbidity and mortality despite many advances. Conventional diagnostics often fail to capture the disease complexity and immune dysregulation, leading to delayed diagnosis and sub-optimal treatment. Recent advances in multiomics, including genomics, transcriptomics, proteomics, metabolomics and metagenomics are transforming molecular understanding by enabling a precise view of host-pathogen interactions. These approaches also provide critical insights into metainflammation, a state of chronic, low-grade immune and metabolic dysregulation, playing a pivotal role in neonatal immune vulnerability. Integrating multi-omics with meta-inflammatory profiling may support future risk stratification, biomarker discovery, and precision-oriented neonatal sepsis care. However, clinical translation requires further validation, platform standardization, and feasibility assessment in NICU settings. Such insights may establish the foundation of P4 medicine by emphasizing prediction, prevention, personalisation, and participation in neonatal care. Multi-omics integration may support endotype identification, and data-driven clinical communication after adequate validation. Overall, this review highlights how multiomics and metainflammation driven frameworks may improve mechanistic understanding of neonatal sepsis and guide future development of clinically feasible precision-medicine approaches.
- 10 June 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1)
Multi-omics insights into immunometabolic dysregulation in neonatal sepsis for precision medicine
Neonatal sepsis remains a major global health challenge, contributing substantially to morbidity and mortality despite many advances. Conventional diagnostics often fail to capture the disease complexity and immune dysregulation, leading to delayed diagnosis and sub-optimal treatment. Recent advances in multiomics, including genomics, transcriptomics, proteomics, metabolomics and metagenomics are transforming molecular understanding by enabling a precise view of host-pathogen interactions. These approaches also provide critical insights into metainflammation, a state of chronic, low-grade immune and metabolic dysregulation, playing a pivotal role in neonatal immune vulnerability. Integrating multi-omics with meta-inflammatory profiling may support future risk stratification, biomarker discovery, and precision-oriented neonatal sepsis care. However, clinical translation requires further validation, platform standardization, and feasibility assessment in NICU settings. Such insights may establish the foundation of P4 medicine by emphasizing prediction, prevention, personalisation, and participation in neonatal care. Multi-omics integration may support endotype identification, and data-driven clinical communication after adequate validation. Overall, this review highlights how multiomics and metainflammation driven frameworks may improve mechanistic understanding of neonatal sepsis and guide future development of clinically feasible precision-medicine approaches.
- 19 April 2026
- Published by Elsevier in Indian Journal of Medical Microbiology
- Vol. 61, 101125
Emergence of vancomycin-variable enterococci in urinary tract infections in north India: A cross-sectional molecular study
- 19 April 2026
- Published by Elsevier in Indian Journal of Medical Microbiology
- Vol. 61, 101125
Emergence of vancomycin-variable enterococci in urinary tract infections in north India: A cross-sectional molecular study
- 3 February 2026
- Published by Springer Nature in Journal of Maxillofacial and Oral Surgery
- p. 1-8
Detection and Relative Quantification of Fusobacterium Nucleatum in Head and Neck Cancers
- 3 February 2026
- Published by Springer Nature in Journal of Maxillofacial and Oral Surgery
- p. 1-8
Detection and Relative Quantification of Fusobacterium Nucleatum in Head and Neck Cancers
- 8 November 2025
- Published by Elsevier in Indian Journal of Medical Microbiology
- Vol. 58, 101005
Phenotypic and genotypic profiling of fosfomycin susceptibility in urinary pathogens isolated from pregnant women in North India
- 8 November 2025
- Published by Elsevier in Indian Journal of Medical Microbiology
- Vol. 58, 101005
Phenotypic and genotypic profiling of fosfomycin susceptibility in urinary pathogens isolated from pregnant women in North India
- 17 October 2025
- Published by Springer Nature in Indian Journal of Orthopaedics
- Vol. 60 (1) , 100-109
Biofilm Formation and Antibiotic Resistance in Orthopaedic Implant Infections: A Molecular Analysis of icaA, icaD, and mecA Genes in an Indian Cohort
Background Orthopaedic implant-related infections (OIRIs) are a major clinical challenge, contributing to increased morbidity, prolonged hospitalisation, and higher healthcare costs. This study investigated the prevalence of biofilm-associated genes (icaA, icaD) in Staphylococcus spp., antimicrobial resistance patterns, and the relationship between implant material, infection rates, and treatment outcomes. Methods This was a cross-sectional study of 200 clinical samples from patients with suspected OIRIs. Pathogens were identified using MALDI-TOF MS, and antimicrobial susceptibility was tested according to CLSI 2023 guidelines. Biofilm formation was assessed by a modified microtiter plate assay, and icaA, icaD, and mecA genes were detected by PCR. Statistical analysis, including chi-square tests and logistic regression, was performed to explore associations between implant material, biofilm genes, and infection risk. Results The mean patient age was 37.99 ± 18.17 years, with males comprising 74%. Fractures were the leading cause of OIRIs (72.5%), predominantly affecting the lower limb (62.5%). Staphylococcus epidermidis (30.2%) and Escherichia coli (15.1%) were the most frequent isolates, with 98% of infections being monomicrobial. Methicillin resistance was common, with 57% of MRSA and 45% of MRSE producing strong biofilms. The icaD gene was significantly associated with biofilm formation (79% in MRSA, 45% in MRSE), whereas icaA showed no such link. Steel implants had the highest infection rate (41.5%), though analysis indicated surgical and patient factors as primary drivers. MDR Gram-negative bacteria displayed high resistance to cephalosporins and fluoroquinolones, with carbapenems and colistin remaining effective. Conclusions OIRIs are strongly influenced by biofilm formation and methicillin resistance. Management should prioritize biofilm-targeted therapies, precision antibiotic use, and implant surface innovations to reduce infection risk and improve outcomes.
- 17 October 2025
- Published by Springer Nature in Indian Journal of Orthopaedics
- Vol. 60 (1) , 100-109
Biofilm Formation and Antibiotic Resistance in Orthopaedic Implant Infections: A Molecular Analysis of icaA, icaD, and mecA Genes in an Indian Cohort
Background Orthopaedic implant-related infections (OIRIs) are a major clinical challenge, contributing to increased morbidity, prolonged hospitalisation, and higher healthcare costs. This study investigated the prevalence of biofilm-associated genes (icaA, icaD) in Staphylococcus spp., antimicrobial resistance patterns, and the relationship between implant material, infection rates, and treatment outcomes. Methods This was a cross-sectional study of 200 clinical samples from patients with suspected OIRIs. Pathogens were identified using MALDI-TOF MS, and antimicrobial susceptibility was tested according to CLSI 2023 guidelines. Biofilm formation was assessed by a modified microtiter plate assay, and icaA, icaD, and mecA genes were detected by PCR. Statistical analysis, including chi-square tests and logistic regression, was performed to explore associations between implant material, biofilm genes, and infection risk. Results The mean patient age was 37.99 ± 18.17 years, with males comprising 74%. Fractures were the leading cause of OIRIs (72.5%), predominantly affecting the lower limb (62.5%). Staphylococcus epidermidis (30.2%) and Escherichia coli (15.1%) were the most frequent isolates, with 98% of infections being monomicrobial. Methicillin resistance was common, with 57% of MRSA and 45% of MRSE producing strong biofilms. The icaD gene was significantly associated with biofilm formation (79% in MRSA, 45% in MRSE), whereas icaA showed no such link. Steel implants had the highest infection rate (41.5%), though analysis indicated surgical and patient factors as primary drivers. MDR Gram-negative bacteria displayed high resistance to cephalosporins and fluoroquinolones, with carbapenems and colistin remaining effective. Conclusions OIRIs are strongly influenced by biofilm formation and methicillin resistance. Management should prioritize biofilm-targeted therapies, precision antibiotic use, and implant surface innovations to reduce infection risk and improve outcomes.
- 22 August 2025
- Published by Elsevier in Indian Journal of Medical Microbiology
- Vol. 57, 100955
Unveiling cystic echinococcosis: Seroprevalence trends and risk dynamics in Northern India
- 22 August 2025
- Published by Elsevier in Indian Journal of Medical Microbiology
- Vol. 57, 100955
Unveiling cystic echinococcosis: Seroprevalence trends and risk dynamics in Northern India
- Open Access
- 19 August 2025
- Published by Scientific Scholar in Journal of Laboratory Physicians
- Vol. 17, 261-265
The potential role of daptomycin and quinupristindalfopristin as a bactericidal agent in the treatment of methicillin-resistant Staphylococcus aureus bacteremia
Objectives: Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia presents considerable clinical problems owing to elevated morbidity, mortality, and antibiotic resistance. This study evaluates the bactericidal efficacy of daptomycin and quinupristin-dalfopristin as potential treatments for MRSA bacteremia. Materials and Methods: This observational study, conducted from September 2017 to March 2018 at a tertiary care referral center in Northern India, analyzed 75 blood isolates of S. aureus. The Kirby–Bauer disc diffusion method and minimum inhibitory concentration testing were used to evaluate antimicrobial susceptibility by the Clinical and Laboratory Standards Institute 2017 standards. A statistical analysis compared the resistance patterns of MRSA and MRSA. Statistical analysis: The results showed that MRSA was much more resistant to aminoglycosides, fluoroquinolones, macrolides, and lincosamides than methicillin-susceptible S. aureus (MSSA), accounting for 70.66% of isolates (P < 0.05). Results: All isolates were completely susceptible to daptomycin; however, MRSA was more resistant to quinupristin-dalfopristin (69.81%) than MSSA (18.18%) (P = 0.00004). Conclusions: The results show that daptomycin is a safer and more effective treatment for MRSA bacteremia, but quinupristin-dalfopristin is still a good option in some situations, even though its resistance rates are higher. The research emphasizes the necessity for customized antimicrobial approaches, continuous monitoring, and combination therapy to address multidrug-resistant MRSA. Quinupristin-dalfopristin may be considered in refractory infections; however, daptomycin is the recommended treatment due to its persistent effectiveness against MRSA. Strategic antibiotic stewardship and novel therapy strategies are essential for enhancing outcomes.
- 19 August 2025
- Published by Scientific Scholar in Journal of Laboratory Physicians
- Vol. 17, 261-265
Open AccessThe potential role of daptomycin and quinupristindalfopristin as a bactericidal agent in the treatment of methicillin-resistant Staphylococcus aureus bacteremia
Objectives: Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia presents considerable clinical problems owing to elevated morbidity, mortality, and antibiotic resistance. This study evaluates the bactericidal efficacy of daptomycin and quinupristin-dalfopristin as potential treatments for MRSA bacteremia. Materials and Methods: This observational study, conducted from September 2017 to March 2018 at a tertiary care referral center in Northern India, analyzed 75 blood isolates of S. aureus. The Kirby–Bauer disc diffusion method and minimum inhibitory concentration testing were used to evaluate antimicrobial susceptibility by the Clinical and Laboratory Standards Institute 2017 standards. A statistical analysis compared the resistance patterns of MRSA and MRSA. Statistical analysis: The results showed that MRSA was much more resistant to aminoglycosides, fluoroquinolones, macrolides, and lincosamides than methicillin-susceptible S. aureus (MSSA), accounting for 70.66% of isolates (P < 0.05). Results: All isolates were completely susceptible to daptomycin; however, MRSA was more resistant to quinupristin-dalfopristin (69.81%) than MSSA (18.18%) (P = 0.00004). Conclusions: The results show that daptomycin is a safer and more effective treatment for MRSA bacteremia, but quinupristin-dalfopristin is still a good option in some situations, even though its resistance rates are higher. The research emphasizes the necessity for customized antimicrobial approaches, continuous monitoring, and combination therapy to address multidrug-resistant MRSA. Quinupristin-dalfopristin may be considered in refractory infections; however, daptomycin is the recommended treatment due to its persistent effectiveness against MRSA. Strategic antibiotic stewardship and novel therapy strategies are essential for enhancing outcomes.
- Open Access
- 4 August 2025
- Published by Academic Science Publications and Distributions in International Journal of Environmental Sciences
- p. 2561-2576
Resistance Mechanisms Of Acinetobacter Baumannii In North Indian Clinical Isolates: A Molecular Study Of Β-Lactam, Carbapenem, Cephalosporin, Fluoroquinolone, And Aminoglycoside Genes
Background- The WHO recently added to priority list Carbapenem-resistant Acinetobacter baumannii (CRAB) major infection cause death throughout the developing world. With time the bacteria have become smarter so antimicrobial resistance is major problem so treatment of infection. Aim- This study explored the relationship between antimicrobial resistance patterns and identified the resistance genes responsible for β-lactam, fluoroquinolone, and aminoglycosides. A. baumannii isolates susceptibility patterns of antimicrobial agent and conventional PCR was used to detection of β-lactamase leading gene to carbapenem- resistant class ( blaSHV, blaTEM, blaVEB, blaPER, blaGES, blaKPC, blaCTX-M-1), (MBL) genes (blaIMP, blaVIM, blaNDM-1), Oxacillinase genes (blaOXA-48, blaOXA-23, blaOXA-24/40, blaOXA-58), Aminoglycoside-modifying enzyme (AME) genes (aac(3)-Ia, aac(3)-IIa, aph(3)-Ia, ant(2)-Ia), Plasmid-mediated quinolone resistance genes (qnrA, qnrB, qnrS), and DNA gyrase genes (parC, gyrA). Results- Resistance genes were detected in 62.09% of blaOXA-23, 15.3% of blaPER, 24.18% of blaNDM, 15.6% of blaSHV-1, 36.6% of parC, 20.26% of aph (3')-VIa, 23.5% of ant(1a), and 9.1% of aac(1a), predominantly in extensively drug-resistant (XDR-AB) isolates. Additionally, 2.6% of blaOXA-58-like genes were found in multidrug-resistant (MDR-AB) isolates. A high prevalence of blaOXA-23-like and specific ESBL genes in extensively drug-resistant (XDR) strains suggests the co-evolution of resistance mechanisms, contributing to enhanced resistance profiles. The co-occurrence of carbapenem resistance genes with aminoglycoside-modifying enzymes or ESBL genes shows A. baumannii versatility and flexibility to acquire several resistance mechanisms; co-resistance is more common in XDR isolates. The high prevalence of blaOXA-23, blaNDM, and parC among resistant isolates means that carbapenem and fluoroquinolone resistance has a major part in the continuing existence of A. baumannii outbreaks.
- 4 August 2025
- Published by Academic Science Publications and Distributions in International Journal of Environmental Sciences
- p. 2561-2576
Open AccessResistance Mechanisms Of Acinetobacter Baumannii In North Indian Clinical Isolates: A Molecular Study Of Β-Lactam, Carbapenem, Cephalosporin, Fluoroquinolone, And Aminoglycoside Genes
Background- The WHO recently added to priority list Carbapenem-resistant Acinetobacter baumannii (CRAB) major infection cause death throughout the developing world. With time the bacteria have become smarter so antimicrobial resistance is major problem so treatment of infection. Aim- This study explored the relationship between antimicrobial resistance patterns and identified the resistance genes responsible for β-lactam, fluoroquinolone, and aminoglycosides. A. baumannii isolates susceptibility patterns of antimicrobial agent and conventional PCR was used to detection of β-lactamase leading gene to carbapenem- resistant class ( blaSHV, blaTEM, blaVEB, blaPER, blaGES, blaKPC, blaCTX-M-1), (MBL) genes (blaIMP, blaVIM, blaNDM-1), Oxacillinase genes (blaOXA-48, blaOXA-23, blaOXA-24/40, blaOXA-58), Aminoglycoside-modifying enzyme (AME) genes (aac(3)-Ia, aac(3)-IIa, aph(3)-Ia, ant(2)-Ia), Plasmid-mediated quinolone resistance genes (qnrA, qnrB, qnrS), and DNA gyrase genes (parC, gyrA). Results- Resistance genes were detected in 62.09% of blaOXA-23, 15.3% of blaPER, 24.18% of blaNDM, 15.6% of blaSHV-1, 36.6% of parC, 20.26% of aph (3')-VIa, 23.5% of ant(1a), and 9.1% of aac(1a), predominantly in extensively drug-resistant (XDR-AB) isolates. Additionally, 2.6% of blaOXA-58-like genes were found in multidrug-resistant (MDR-AB) isolates. A high prevalence of blaOXA-23-like and specific ESBL genes in extensively drug-resistant (XDR) strains suggests the co-evolution of resistance mechanisms, contributing to enhanced resistance profiles. The co-occurrence of carbapenem resistance genes with aminoglycoside-modifying enzymes or ESBL genes shows A. baumannii versatility and flexibility to acquire several resistance mechanisms; co-resistance is more common in XDR isolates. The high prevalence of blaOXA-23, blaNDM, and parC among resistant isolates means that carbapenem and fluoroquinolone resistance has a major part in the continuing existence of A. baumannii outbreaks.
- Open Access
- 1 August 2025
- Published by Microbiology Society in Access Microbiology
- Vol. 7 (8) , 000787.v4
A hospital-based observational study on HIV-TB co-infection
Background. Human immunodeficiency virus (HIV) is the major cause of failure to reach targets of tuberculosis (TB) control in settings with high HIV loads. TB, on the other hand, enhances the progression of HIV infection to AIDS. This study was done to understand the epidemiological and clinical profile of HIV-TB co-infected patients and to study the impact of TB on the recovery of CD4 counts. Methodology. An observational study was conducted in which of the 573 patients newly diagnosed with HIV infection and enrolled at the antiretroviral therapy (ART) centre, King George’s Medical University, Lucknow, between May 2021 and June 2022, 80 patients who also had newly diagnosed TB were included. These HIV-TB co-infected patients were analysed for demographic factors. Also, clusters of differentiation 4 (CD4) counts were done at the time of enrolment on ART and then later, ~6 to 8 months of recieving ART and anti-tubercular treatment (ATT) initiation. For comparison, of the 493 HIV-only patients, 50 age- and gender-matched consecutive patients for whom baseline and follow-up CD4 counts were available were enrolled as controls. The change from baseline CD4 count was calculated using a paired t-test and Wilcoxon signed rank test. Results. In the present study, among HIV-TB co-infected patients, baseline CD4 levels were 194.52±162.27, and follow-up CD4 levels were 285.09±170.33. A statistically significant increment of 90.57±165.60 in mean CD4 levels was observed (t=4.019; Pt=4.626; PConclusion. Though significant rise in CD4 counts was observed in both HIV-TB co-infected patients and HIV-only patients after 6 to 8 months of appropriate therapy, the rise was significantly higher among the HIV-only group as compared to the HIV-TB co-infected group.
- 1 August 2025
- Published by Microbiology Society in Access Microbiology
- Vol. 7 (8) , 000787.v4
Open AccessA hospital-based observational study on HIV-TB co-infection
Background. Human immunodeficiency virus (HIV) is the major cause of failure to reach targets of tuberculosis (TB) control in settings with high HIV loads. TB, on the other hand, enhances the progression of HIV infection to AIDS. This study was done to understand the epidemiological and clinical profile of HIV-TB co-infected patients and to study the impact of TB on the recovery of CD4 counts. Methodology. An observational study was conducted in which of the 573 patients newly diagnosed with HIV infection and enrolled at the antiretroviral therapy (ART) centre, King George’s Medical University, Lucknow, between May 2021 and June 2022, 80 patients who also had newly diagnosed TB were included. These HIV-TB co-infected patients were analysed for demographic factors. Also, clusters of differentiation 4 (CD4) counts were done at the time of enrolment on ART and then later, ~6 to 8 months of recieving ART and anti-tubercular treatment (ATT) initiation. For comparison, of the 493 HIV-only patients, 50 age- and gender-matched consecutive patients for whom baseline and follow-up CD4 counts were available were enrolled as controls. The change from baseline CD4 count was calculated using a paired t-test and Wilcoxon signed rank test. Results. In the present study, among HIV-TB co-infected patients, baseline CD4 levels were 194.52±162.27, and follow-up CD4 levels were 285.09±170.33. A statistically significant increment of 90.57±165.60 in mean CD4 levels was observed (t=4.019; Pt=4.626; PConclusion. Though significant rise in CD4 counts was observed in both HIV-TB co-infected patients and HIV-only patients after 6 to 8 months of appropriate therapy, the rise was significantly higher among the HIV-only group as compared to the HIV-TB co-infected group.